You spent four weeks priming the substrate. CJC-1295 plus Ipamorelin restored pulsatile GH architecture, BPC-157 and TB-500 quieted the connective tissue, and sleep started carrying recovery instead of sabotaging it. Now you graduate from systemic conditioning to site-directed anabolism. Phase 2 is where the recomp window opens — and where the protocol stops being forgiving.
Two compounds enter the stack: IGF-1 LR3 for surgical, post-workout muscle-fiber stimulation, and MK-677 for sustained nighttime GH amplitude plus the ghrelin-driven appetite signal that makes a hypercaloric build sustainable. Phase 1 stays exactly where it was. You're not replacing — you're layering.
What's actually happening at the cellular level
IGF-1 LR3 is not "more IGF-1." It's a re-engineered IGF-1 molecule with an arginine-3 substitution and a 13-amino-acid N-terminal extension. The substitution prevents IGFBP binding, which is what makes endogenous IGF-1 short-lived in circulation. The result, per the practitioner corpus: roughly 10x the potency of native IGF-1, paired with a very short half-life of 20-30 minutes. That short half-life is the feature, not a flaw. It means a post-workout intramuscular injection saturates IGF-1 receptors in the target tissue, drives local hypertrophic and hyperplastic signaling, and clears before systemic IGF-1 receptors get hammered downstream.
Two distinct anabolic responses are at play. Hypertrophy — the increase in muscle fiber cross-sectional area — comes from IGF-1 receptor-driven mTOR activation and protein synthesis. Hyperplasia — the increase in muscle fiber number via satellite cell proliferation and fusion — is the rarer mechanism, and IGF-1 LR3 is one of the few compounds in the practitioner toolkit that meaningfully activates it. When you inject bilaterally into a lagging muscle group post-workout, you are recruiting both pathways simultaneously in a tissue that just generated the mechanical and metabolic substrate to respond.
MK-677 (ibutamoren) is a different animal entirely. It's an oral ghrelin receptor mimetic — meaning it activates the same receptor that endogenous ghrelin (your stomach's hunger hormone) activates, including the receptor on pituitary somatotrophs that triggers GH release. The practitioner corpus reports that effective dosing produces results "nearly identical" to modest daily HGH injections — with gains of 5-10 pounds of fat-free mass commonly reported in the first few weeks. One quantification: MK-677 has demonstrated potential to offset aging-induced catabolism by as much as 29%. The clinical signal flattens above 25 mg/day — diminishing returns dominate past that dose, while side effects climb.
Three downstream consequences matter for protocol design:
- Nitrogen balance shifts positive. This is the underlying mechanism for the muscle retention and growth seen across reported trials — building muscle without forcing the protein intake required to achieve positive nitrogen balance through diet alone.
- REM and slow-wave sleep architecture deepens. GH pulsatility through the night is amplified, which is why nightly dosing pairs with the natural sleep-time GH surge.
- Ghrelin agonism drives appetite hard. This is desirable in a build phase. It is the reason MK-677 belongs in a recomp/gain protocol and not a cut.
The interaction with the Phase 1 stack is synergistic, not redundant. CJC-1295 sets the GHRH-mediated baseline. Ipamorelin delivers the clean nighttime ghrelin-receptor pulse. MK-677 amplifies that ghrelin signal and extends it across 24 hours via its ~24-hour half-life. IGF-1 LR3 then operates one rung downstream of GH — direct receptor activation at the muscle level, bypassing the GH→hepatic IGF-1 conversion bottleneck.
Phase 2 stack (Weeks 5-10)
Phase 1 compounds continue at their established doses. Add the following:
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| IGF-1 LR3 | [practitioner corpus thin on precise mcg — track and report] | Intramuscular (direct into target muscle) or SubQ | Immediately post-workout, training days only | 🟣 Experimental | Site-specific IM into lagging muscle group; bilateral injection pattern. Short half-life (~20-30 min) means timing window is narrow. Never combine with exogenous insulin without explicit monitoring. |
| MK-677 (Ibutamoren) | Start 12.5 mg, titrate toward 25 mg | Oral | Nightly, before bed | 🟢 Expert | Hard ceiling at 25 mg/day — diminishing returns above. Expect appetite increase and water retention in first 2 weeks. |
| CJC-1295 (DAC) | 2 mg | SubQ | 1x/week (any day) | 🟢 Expert | Continuing from Phase 1. 8+ day half-life. |
| Ipamorelin | 100-200 mcg | SubQ | 2x/day — morning fasted + before bed | 🟢 Expert | Continuing from Phase 1. Night dose stacks with sleep-time GH surge. |
| BPC-157 | 250 mcg | SubQ, abdomen-near | 2x/day | 🟢 Expert | Continuing from Phase 1 — keeps connective tissue ahead of the new loading. |
| TB-500 | 2.0-2.5 mg | SubQ | Loading dose 1x/week through Week 8, then taper | 🟢 Expert | Continuing recovery substrate; supports the heavier training volume Phase 2 enables. |
Glucose discipline is non-negotiable on this stack. Two substrate rules govern Phase 2 entry:
- Fasting insulin must be below 8 mIU/L before you started GH secretagogues in Phase 1. If you bypassed that gate, stop now and pull labs. GH antagonizes insulin, and IGF-1 LR3 layered on top of secretagogues compounds the metabolic load.
- If serum IGF-1 climbs above 350 ng/mL, insulin sensitivity must be monitored even without exogenous insulin. This is the threshold where the practitioner corpus flags risk that demands bloodwork tracking and dose adjustment.
The pragmatic glucose tactic: shift the bulk of your carbohydrate load to the dinner window (100-200g from millet, sweet potato, white rice, yam) to capitalize on the evening insulin-sensitivity peak — and to support the nighttime MK-677/Ipamorelin GH surge with the recovery substrate. Avoid post-IGF-1 LR3 fasted states; have your training-day carbs queued.
What you should feel
Week 5-6. Appetite climbs noticeably within 3-5 days of starting MK-677 — this is ghrelin-receptor agonism doing exactly what it should. Mild peripheral water retention (face, hands, ankles) typically appears in the same window and stabilizes by Week 7. Sleep quality deepens; REM lengthens.
Week 6-8. Localized fullness in the muscle group receiving IGF-1 LR3 post-workout. Lifts in that muscle group move faster than the systemic baseline. Recovery between high-volume sessions tightens — the substrate consistently describes this as the window where layered GH + IGF + recovery peptides start producing the recomp signal.
Week 8-10. Body composition shift becomes visually obvious. Fat-free mass gains in the 5-10 lb range over the full Phase 2 window are within the reported envelope when training and nutrition are dialed.
What's NOT happening yet
- You are not getting "free" gains. MK-677 elevates appetite for a reason — the protocol assumes a hypercaloric intake matched to training stimulus. Eat under maintenance and you blunt the entire stack.
- The water retention is not fat gain. It's expected, it's GH-axis-mediated, and it resolves on cycle-off. Don't chase it with diuretics mid-cycle.
- IGF-1 LR3 is not a systemic anabolic. Injecting it SubQ in the abdomen and expecting whole-body growth misses the mechanism. The short half-life is what makes site-specific injection viable — use it.
- Strength PRs are not the marker. Body composition (DEXA, calipers, mirror) and IGF-1 serum trend are the markers. Strength lags hypertrophy by weeks at this layering.
- Do not stack exogenous insulin onto IGF-1 LR3 to "push it further." The practitioner corpus is explicit: adding insulin to an IGF injection scenario significantly increases adverse-event risk, including the bloated-midsection presentation seen in misuse cases.
The risks of injecting IGF willy-nilly are very real — track IGF-1, fasting glucose, and fasting insulin every four weeks on this stack and adjust.